News
This was the stock's second consecutive day of gains.
Genmab reported strong Phase 3 trial results for epcoritamab in FL, secured FDA priority review, and raised its 2025 sales ...
Barchart on MSN6d
AbbVie Stock Outlook: Is Wall Street Bullish or Bearish?Despite AbbVie’s underperformance relative to the S&P 500 over the past year, Wall Street analysts maintain a moderately ...
Although it sounds like an oxymoron, high-growth prospect dividend aristocrat stocks exist, although their industries may ...
Chronic Lymphocytic Leukemia Therapeutics Market to Grow at 7% CAGR Driven by Targeted Drugs by 2030
The chronic lymphocytic leukemia therapeutics market is expected to grow at a compound annual growth rate of 7% from 2025 to ...
Zacks Investment Research on MSN6d
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should KnowAbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...
At first glance, Pfizer delivered a strong Q2 and upped its 2025 full-year EPS guidance. Click here to find out why I rate ...
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies ...
Personalized medicine market growth PORTLAND, OR, UNITED STATES, August 11, 2025 /EINPresswire / -- The global personalized medicine market , ...
Allergan Aesthetics scored a big legal patent infringement win tied to its blockbuster wrinkle-treatment Botox. A federal ...
REGENXBIO to initiate pivotal phase IIb/III clinical trial of surabgene lomparvovec in diabetic retinopathy: Rockville, Maryland Friday, August 8, 2025, 15:00 Hrs [IST] REGENXBIO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback